Collegium Pharmaceutical, Inc. $COLL Shares Bought by NewEdge Wealth LLC

NewEdge Wealth LLC grew its position in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 59.6% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 38,893 shares of the specialty pharmaceutical company’s stock after purchasing an additional 14,529 shares during the quarter. NewEdge Wealth LLC owned approximately 0.12% of Collegium Pharmaceutical worth $1,286,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Group One Trading LLC acquired a new stake in shares of Collegium Pharmaceutical in the 4th quarter valued at about $28,000. Caitong International Asset Management Co. Ltd increased its position in Collegium Pharmaceutical by 205.3% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 635 shares of the specialty pharmaceutical company’s stock worth $29,000 after buying an additional 427 shares during the period. Kemnay Advisory Services Inc. purchased a new stake in Collegium Pharmaceutical in the fourth quarter valued at approximately $61,000. PNC Financial Services Group Inc. lifted its stake in Collegium Pharmaceutical by 42.2% in the first quarter. PNC Financial Services Group Inc. now owns 1,408 shares of the specialty pharmaceutical company’s stock valued at $47,000 after buying an additional 418 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Collegium Pharmaceutical by 26.1% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,536 shares of the specialty pharmaceutical company’s stock valued at $71,000 after acquiring an additional 318 shares during the period.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on COLL. Wall Street Zen lowered shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Zacks Research upgraded shares of Collegium Pharmaceutical from a “hold” rating to a “strong-buy” rating in a research report on Monday, June 29th. Weiss Ratings reiterated a “hold (c)” rating on shares of Collegium Pharmaceutical in a research note on Monday, July 6th. Finally, Truist Financial raised shares of Collegium Pharmaceutical to a “strong-buy” rating in a research report on Monday, June 15th. Two research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, Collegium Pharmaceutical presently has an average rating of “Buy” and an average price target of $57.50.

Collegium Pharmaceutical Price Performance

Shares of NASDAQ COLL opened at $35.20 on Monday. The stock has a fifty day moving average price of $34.65 and a 200 day moving average price of $37.88. Collegium Pharmaceutical, Inc. has a 1-year low of $29.19 and a 1-year high of $50.79. The company has a debt-to-equity ratio of 2.47, a current ratio of 1.71 and a quick ratio of 1.62. The company has a market cap of $1.14 billion, a PE ratio of 17.25 and a beta of 0.73.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings data on Thursday, May 7th. The specialty pharmaceutical company reported $1.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.52 by $0.24. Collegium Pharmaceutical had a net margin of 9.41% and a return on equity of 95.18%. The company had revenue of $193.52 million for the quarter, compared to analysts’ expectations of $184.47 million. During the same period in the previous year, the company posted $1.49 EPS. Collegium Pharmaceutical’s revenue was up 8.9% compared to the same quarter last year. Sell-side analysts forecast that Collegium Pharmaceutical, Inc. will post 6.76 EPS for the current year.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.